Outlook Therapeutics (OTLK) Equity Income (2021 - 2026)
Outlook Therapeutics (OTLK) reported Equity Income of -$45119.0 for Q1 2026, down 23.92% year-over-year from -$59306.8 in Q1 2025, and down 16.79% quarter-over-quarter from -$38634.0 in Q4 2025.
Outlook Therapeutics (OTLK) Equity Income (2021 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 6 years of Equity Income data on file, last reported at -$45119.0 in Q1 2026.
- Equity Income for Q1 2026 came in at -$45119.0, down 23.92% year-over-year; the trailing twelve-month figure through Mar 2026 was -$155056.0 (down 8.89% YoY), and the FY2025 annual result was -$141007.0, down 39.97% from the prior year.
- Equity Income eased to -$45119.0 in Q1 2026 per OTLK's latest filing, from -$38634.0 in the prior quarter.
- Over five years, Equity Income peaked at $21505.0 in Q4 2022 and troughed at -$57497.0 in Q2 2024.
- A 5-year average of -$21269.1 and a median of -$16965.0 in 2023 frame the typical range for Equity Income.
- The sharpest annual moves came in 2022 and 2024: Equity Income jumped 190.91% in 2022, then tumbled 1406.71% in 2024.
- A 5-year view of Equity Income shows it stood at $21505.0 in 2022, then plunged by 88.15% to $2548.0 in 2023, then plunged by 1406.71% to -$33295.0 in 2024, then dropped by 16.04% to -$38634.0 in 2025, then fell by 16.79% to -$45119.0 in 2026.
- Business Quant data shows OTLK's Equity Income at -$45119.0 in Q1 2026, -$38634.0 in Q4 2025, and -$40419.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 | -45,119.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45,119.00 |
| Dec 31, 2025 | -38,634.00 |
| Sep 30, 2025 | -40,419.00 |
| Jun 30, 2025 | -30,884.00 |
| Mar 31, 2025 | -36,409.00 |
| Dec 31, 2024 | -33,295.00 |
| Sep 30, 2024 | -15,198.00 |
| Jun 30, 2024 | -57,497.00 |
| Mar 31, 2024 | -30,595.00 |
| Dec 31, 2023 | 2,548.00 |
| Sep 30, 2023 | -8,350.00 |
| Jun 30, 2023 | -7,188.00 |
| Mar 31, 2023 | -16,965.00 |
| Dec 31, 2022 | 21,505.00 |
| Sep 30, 2022 | -7,226.00 |
| Jun 30, 2022 | -11,805.00 |
| Mar 31, 2022 | -6,044.00 |
| Dec 31, 2021 | -23,655.00 |
| Sep 30, 2021 | 389,006.00 |
| Jun 30, 2021 | -435,346.00 |